Literature DB >> 6175730

Involvement of the kidney in catabolism of human leukocyte interferon.

T Bino, H Edery, A Gertler, H Rosenberg.   

Abstract

The metabolic fate of human leukocyte interferon (HuIFN-alpha) was studied after intravenous injection into rats and cynomolgus monkeys. At various intervals the animals were sacrificed and the HuIFN-alpha content determined in serum and various tissues. HuIFN-alpha quickly disappeared from the circulation and was found mainly in the kidneys, in which levels were at least 7- to 10-fold higher than in the liver, spleen, lungs, heart, brain and muscles. No interferon was detected in urine. Subcellular fractionation of kidney revealed that the mitochondrial-lysosomal fraction (15 000 g) had a high HuIFN-alpha content. It was also found that HuIFN-alpha was rapidly inactivated by two types of proteinases found in the lysosomal fractions of rat, monkey and human kidneys, with an optimal pH of 3 to 4. The inactivation was partially inhibited by either pepstatin or leupeptin. Inactivation was totally prevented by a mixture of both inhibitors. Since it is known that interferon is scantily excreted in urine, our findings suggest that the kidney serves as a main site for its degradation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175730     DOI: 10.1099/0022-1317-59-1-39

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice.

Authors:  D S Wang; S Ohdo; S Koyanagi; H Takane; H Aramaki; E Yukawa; S Higuchi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Scintigraphic study of radiolabelled interferon-alpha in osteosarcoma patients.

Authors:  R A Diez; B Perdereau; M Peter; T Dorval; R Gongora; E T Falcoff
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.

Authors:  Leonid Kagan; Anson K Abraham; John M Harrold; Donald E Mager
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

5.  The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function.

Authors:  Matthew W Hruska; Robert Adamczyk; Elizabeth Colston; Michael Hesney; Michele Stonier; Heather Myler; Richard Bertz
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

Review 6.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Renal deposition of alpha interferon in systemic lupus erythematosus.

Authors:  S Panem; N Ordóñez; J Vilcek
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.